Novavax (NASDAQ:NVAX) Trading Down 7.3% – What’s Next?

Novavax, Inc. (NASDAQ:NVAX) shares were down 7.3% on Thursday . The company traded as low as $10.36 and last traded at $10.2830. Approximately 930,816 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 4,942,366 shares. The stock had previously closed at $11.09.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax rallied after reports that FDA advisers will consider updating the 2026-27 COVID-19 vaccines to target the latest XFG subvariant, potentially improving demand for vaccine makers including Novavax. Why Novavax (NVAX) Stock Is Trading Up Today
• Positive Sentiment: Options trading turned unusually bullish, with investors buying 21,279 Novavax call contracts, about 50% above typical volume, indicating increased speculation on further stock gains.
• Positive Sentiment: Zacks Research raised multiple earnings estimates for Novavax, including FY2026, FY2027, FY2028, and several interim quarters, signaling improving expectations for the company’s future profitability.
• Neutral Sentiment: Short-interest data showed no meaningful shares outstanding in the latest report, so it does not currently provide a clear near-term trading signal.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on NVAX shares. HC Wainwright lifted their price objective on Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, February 27th. Wall Street Zen lowered Novavax from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Novavax in a report on Thursday, March 12th. TD Cowen lifted their price objective on Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. Finally, B. Riley Financial reaffirmed a “buy” rating on shares of Novavax in a report on Thursday, April 9th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $12.13.

Novavax Stock Performance

The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -17.73 and a beta of 2.37. The company has a 50-day moving average of $8.85 and a 200-day moving average of $8.32.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.19. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The firm had revenue of $118.90 million during the quarter, compared to the consensus estimate of $79.81 million. During the same period in the previous year, the firm posted $2.93 EPS. The company’s quarterly revenue was down 79.0% compared to the same quarter last year. As a group, analysts expect that Novavax, Inc. will post -0.19 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NVAX. Shah Capital Management raised its position in shares of Novavax by 23.3% during the 4th quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock worth $97,835,000 after purchasing an additional 2,747,000 shares during the last quarter. State Street Corp raised its position in shares of Novavax by 32.3% during the 4th quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock worth $63,999,000 after purchasing an additional 2,326,927 shares during the last quarter. UBS Group AG raised its position in shares of Novavax by 40.3% during the 4th quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock worth $32,890,000 after purchasing an additional 1,405,981 shares during the last quarter. Allianz Asset Management GmbH raised its position in shares of Novavax by 162.6% during the 3rd quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock worth $12,222,000 after purchasing an additional 872,987 shares during the last quarter. Finally, Farallon Capital Management LLC raised its position in shares of Novavax by 4,775.0% during the 3rd quarter. Farallon Capital Management LLC now owns 780,000 shares of the biopharmaceutical company’s stock worth $6,763,000 after purchasing an additional 764,000 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.